



For Information Contact:

Andrew T. Jewett, Director
Hospital Preparedness Program
Iroquois Healthcare Association
315-410-6470 / ajewett@iroquois.org

08/25/09

[CDC 8/20/09 H1N1 Briefing Summary](#)

CDC hosted a telephone briefing August 20th to provide an update on H1N1 investigation and H1N1 vaccine development. The briefing featured CDC's Dr. Jay Butler – head of H1N1 Task Force, FDA's Dr. Jesse Goodman and NIH's Dr. Anthony Fauci. The highlights were:

Activity Update

U.S. – Low levels of flu activity currently; almost all novel strain; normally do not have any at this time of year

Alaska and Maine reporting widespread activity

Disproportionately effects younger population

Sub-typing is similar to that provided for the vaccine

Appears to be susceptible to antiviral drugs

Southern Hemisphere - Activity in decline

Similar to what we saw in spring, no changes in virus or activity

U.K. – Decreases in disease

Japan - Increasing

Vaccination Update

45-52 million doses expected by mid October

Weekly additions to availability up to 195 million by year's end

5 manufacturers working to produce maximum capacity

Distribution plan is developing

Initial distribution to be based on states' population

Providers to order from state, manufacturers to ship to state with ancillary supplies

Target/priority groups (See attached ACIP Vaccination Recommendations)

Pregnant woman

People who are 6 m – 24 years of age

25-64 with underlying medical conditions

HCW + EMS

People caring for infants under 6 months

Clinical Trials Update

FDA, NIH, CDC working together for:

- Oversight of quality and safety of vaccine manufacture
- Increase capacity in production and back-up capacity

Pilot lots to 8 clinical trial sites in progress “going well”

- 15 vs 30 mcg studies
- 1 dose vs 2 dose studies
- Both studies are fully enrolled

First dose data expected mid September; Second dose data mid October

No red flags have come up yet, which permitted them to begin the pediatric trials and pregnant woman trials

Obesity as a special consideration? More studies will be done, to determine if obese patients should be included in the priority vaccination groups

Virus mixing – turkeys with swine flu in Argentina were reported this morning (8/20) raising reassortment of swine and avian concerns.

Rate of infection in children is high; death rate is comparable to seasonal flu for pediatric population.